Lonza

Lonza: the Swiss-listed group will make its trading debut on SGX mainboard at 9am today as Spore’s first Swiss-listed co to be secondary listed here.
The co. is a supplier to the pharmaceutical, healthcare and life sciences industries headquartered in Basel, Switzerland.
All dealings in the shares on the SGX will be conducted in SGD in board lots of 10 shares or integral multiples thereof.
Based on the company's closing market price of CHF 56.35, or S$79.05, on the SIX on Oct 19, it has a market cap of ~ CHF 2,982 m (US$3,315 m). This corresponds to ~S$4,183 m based on an exchange rate of CHF 1.00 to SGD 1.4028.
For FY10, Lonza reported sales of CHF 2,680m, +3.3% yoy. Net profit rose to CHF 284m, +10.4% yoy.